Jump to contents

Researcher Information

last modified:2021/05/29

Associate Professor TAKAMATSU, Hiroyuki

Faculty, Affiliation

Faculty of Transdisciplinary Sciences, Institute of Philosophy in Interdisciplinary Sciences

College and School Educational Field


Laboratory

Hematology & Respirology

Academic Background

【Academic background(Doctoral/Master's Degree)】
Kanazawa University Doctor Completed
【Academic background(Bachelor's Degree)】
Kanazawa University
【Degree】
MD, PhD

Career

Year & Month of Birth

Academic Society






European Hematology Association
The American Society of Hematology





The Japanese Society of Hematology



Award



Specialities

Hematology

Speciality Keywords

Research Themes

Books

Papers

  •  A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.  Hiroyuki Takamatsu (Corresponding author), Rachel K Wee, Yoshitaka Zaimoku, Ryoichi Murata, Jianbiao Zheng, Martin Moorhead, Victoria E. H. Carlton, Katherine A. Kong, Naoki Takezako, Shigeki Ito, Toshihiro Miyamoto, Kenji Yokoyama, Kosei Matsue, Tsutomu Sato, Toshiro Kurokawa, Hideo Yagi, Yasushi Terasaki, Kinya Ohata, Morio Matsumoto, Takashi Yoshida, Malek Faham and Shinji Nakao.  Br J Haematol 2017/09/01
  •  Comparison of minimal residual disease detection by multiparameter flow cytometry, ASO-qPCR, droplet digital PCR, and deep sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. Hiroyuki Takamatsu  Journal of Clinical Medicine 6 10 91 2017/06/01
  •  Identification of an HLA class I allele closely involved in the auto-antigen presentation in acquired aplastic anemia. Zaimoku Y, Takamatsu H, Hosomichi K, Ozawa T, Nakagawa N, Imi T, Maruyama H, Katagiri T, Kishi H, Tajima A, Muraguchi A, Kashiwase K, Nakao S. Blood 2017
  •  Successful hyperbaric oxygen therapy for refractory BK virus-associated hemorrhagic cystitis after cord blood transplantation Hosokawa K, Yamazaki H, Nakamura T, Yoroidaka T, Imi T, Shima Y, Ohata K, Takamatsu H, Kotani T, Kondo Y, Takami A, Nakao S Transpl Infect Dis 2014
  •  造血幹細胞移植後のガンマグロブリン予防投与(0.1g/kg/週)の有効性の検討:単一施設での後方視的解析 高松博幸、材木義隆、丸山裕之、細川晃平、斉藤千鶴、清木ゆう、大畑欣也、望月果奈子、小谷岳春、近藤恭夫、山崎宏人、高見昭良、中尾眞二 日本輸血・細胞治療学会誌 59 1 43-47 2013

show all

  •  Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosisPhase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis Chihiro Shimazaki, Shin‑ichi Fuchida, Kenshi Suzuki, Tadao Ishida, Hirokazu Imai, Morio Sawamura, Hiroyuki Takamatsu, Masahiro Abe, Toshihiro Miyamoto, Hiroyuki Hata, Masahito Yamada, Yukio Ando Int J Hematol 103 79-85 2016
  •  Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era Hiroyuki Takamatsu, Sumihisa Honda, Toshihiro Miyamoto, Kenji Yokoyama, Shotaro Hagiwara, Toshiro Ito, Naoto Tomita, Shinsuke Iida, Toshihiro Iwasaki, Hisashi Sakamaki, Ritsuro Suzuki, Kazutaka Sunami Cancer Science 106 2 179-185 2015
  •  Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation Kawamura K, Takamatsu H, Ikeda T, Komatsu T, Aotsuka N, Amano I, Yamamoto G, Watanabe K, Ohno Y, Matsue K, Kouzai Y, Tsukada N, Ishiyama K, Anzai N, Kato K, Suzuki R, Sunami K, Kanda Y Biol Blood Marrow Transplant 21 7 1291 2015
  •   t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs Shinsuke Iida, Tomoko Narita, Atsushi Inagaki, Tsutomu Kobayashi, Yoshiaki Kuroda, Toshihiro Fukushima, Masahiko Nezu, Shinichi Fuchida, Hirotaka Sakai, Naohiro Sekiguchi, Isamu Sugiura, Yoshinobu Maeda, Hiroyuki Takamatsu, Norifumi Tsukamoto, Dai Maruyama, Yasushi Kubota, Minoru Kojima, Kazutaka Sunami, Takaaki Ono, Masaki Ri, and Kensei Tobinai Blood Cancer Journal 27 5 e285 2015
  •  Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia Dao AT, Yamazaki H, Takamatsu H, Sugimori C, Katagiri T, Maruyama H, Zaimoku Y, Maruyama K, Ly TQ, Espinoza L, Nakao S Ann Hematol 95 5 771-81 2016
  •  骨髄腫患者の経過観察中に必要な検査 52 12 2156-2160 2015
  •  Epstein–Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation Hiroyuki Takamatsu Journal of Clinical Virology 80 82-86 2016
  •  Role of Moesin in Murine Hematopoiesis Takamatsu, Hiroyuki;Espinoza, Luis J.;Nakao, Shinji BLOOD 118 21 589-590 2011
  •  Aplastic anemia successfully treated with rituximab: the possible role of aplastic anemia-associated autoantibodies as a marker for response Takamatsu, Hiroyuki;Yagasaki, Hiroshi;Takahashi, Yoshiyuki;Hama, Asahito;Saikawa, Yutaka;Yachie, Akihiro;Koizumi, Shoichi;Kojima, Seiji;Nakao, Shinji EUROPEAN JOURNAL OF HAEMATOLOGY 86 6 541-545 2011
  •  Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma Takamatsu, Hiroyuki; Munemoto, Saori; Murata, Ryoichi; Terasaki, Yasushi; Nakajima, Kenichi; Nakao, Shinji Anticancer Research 33 12 5681-5685 2013/12/01 
  •  Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides Takamatsu, Hiroyuki; Ogawa, Yoshiyasu; Kobayashi, Noriko; Obata, Kazue; Narisawa, Tadashi; Nakayama, Kouji; Munemoto, Saori; Aoki, Go; Ohata, Kinya; Kumano, Yoshihisa; Ozaki, Jun; Murata, Ryoichi; Kondo, Yukio; Terasaki, Yasushi; Kurokawa, Toshiro; Miyamoto, Toshihiro; Shimizu, Naomi; Fukushima, Toshihiro; Yoshida, Akira; Ueda, Takanori; Yoshida, Takashi; Nakao, Shinji Experimental Hematology 41 10 894-902 2013/10/01 
  •  Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem cell transplantation. Hiroyuki Takamatsu (Corresponding author), Naoki Takezako, Jianbiao Zheng, Martin Moorhead, Victoria E. H. Carlton, Katherine A. Kong, Ryoichi Murata, Shigeki Ito, Toshihiro Miyamoto, Kenji Yokoyama, Kosei Matsue, Tsutomu Sato, Toshiro Kurokawa, Hideo Yagi, Yasushi Terasaki, Kinya Ohata, Morio Matsumoto, Takashi Yoshida, Malek Faham and Shinji Nakao.  Ann Oncol 28 2503-2510 2017
  •  Detection of Minimal Residual Disease in Patients with Multiple Myeloma by PCR-Based IGH Gene Clonality Analysis Using DNA Extracted From Archival Bone Marrow Slides Takamatsu, Hiroyuki;Ogawa, Yoshiyasu;Kobayashi, Noriko;Obata, Kazue;Narisawa, Tadashi;Nakayama, Kouji;Nakao, Shinji BLOOD 118 21 820-821 2011
  •  Thymoglobuline Is As Effective As Lymphoglobuline in Japanese Patients with Aplastic Anemia Possessing Increased Glycosylphosphatidylinositol-Anchored Protein (GPI-AP) Deficient Cells Yamazaki, Hirohito;Saito, Chizuru;Sugimori, Naomi;Hosokawa, Kohei;Kiyu, Yu;Mochizuki, Kanako;Takamatsu, Hiroyuki;Nakao, Shinji BLOOD 118 21 590-590 2011
  •  Detection of antibodies against human leukocyte antigen class II in the sera of patients receiving intravenous immunoglobulin. Hiroyuki Takamatsu, Shinya Yamada, Noriharu Nakagawa, Erika Matsuura, Atsuo Kasada, Keijiro Sato, Kohei Hosokawa, Noriko Iwaki, Masahisa Arahata, Hidenori Tanaka, Shinji Nakao. Transplantation Direct 2021
  •  HLA class I allele-lacking leukocytes predict rare clonal evolution to MDS/AML in patients with acquired aplastic anemia.  Kohei Hosokawa, Hiroki Mizumaki, Takeshi Yoroidaka, Hiroyuki Maruyama, Tatsuya Imi, Noriaki Tsuji, Ryota Urushibara, Mikoto Tanabe, Yoshitaka Zaimoku, Mai Anh Thi Nguyen, Dung Cao Tran, Ken Ishiyama, Hirohito Yamazaki, Takamasa Katagiri, Hiroyuki Takamatsu, Kazuyoshi Hosomichi, Atsushi Tajima, Fumihiro Azuma, Seishi Ogawa, and Shinji Nakao. Blood 2021
  •  Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study. Sunami K, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Kaneko H, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Takahashi K, Tada K, Macé S, Guillemin-Paveau H, Iida S.  Cancer Sci. 111 12 4526 2020
  •  Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. Fujisaki T, Ishikawa T, Takamatsu H, Suzuki K, Min CK, Lee JH, Wang J, Carson R, Crist W, Qi M, Nagafuji K. Ann Hematol. 98 12 2805 2019
  •  Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. Takamatsu H (Corresponding author), Iida S, Shibayama H, Shibayama K, Yamazaki H, Suzuki K. Int J Hematol. 111 5 692 2020
  •  Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12). Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K. Int J Clin Oncol. 2019/04/01
  •  Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid. Arahata M, Takamatsu H, Morishita E, Kadohira Y, Yamada S, Ichinose A, Asakura H. Int J Hematol. 111 4 550 2020
  •  Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.  Ishida T, Kimura H, Ozaki S, Kubo K, Sunami K, Takezako N, Fujita H, Hayashi T, Kiguchi T, Ohashi K, Yamamoto S, Takamatsu H, Kosugi H, Ohta K, Sakai R, Handa H, Kondo S, Abe Y, Omoto E, Mitani K, Morita S, Murakami H, Shimizu K. Ann Hematol. 99 5 1063 2020
  •  Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. Sakurai M, Mori T, Uchiyama H, Ago H, Iwato K, Eto T, Iwasaki H, Kawata T, Takamatsu H, Yamasaki S, Takanashi M, Ichinohe T, Atsuta Y, Suzuki R. Ann Hematol.  99 7 1635 2020
  •  A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia.  Mizumaki H, Hosomichi K, Hosokawa K, Yoroidaka T, Imi T, Zaimoku Y, Katagiri T, Nguyen MAT, Tran DC, Elbadry MIY, Chonabayashi K, Yoshida Y, Takamatsu H, Ozawa T, Azuma F, Kishi H, Fujii Y, Ogawa S, Tajima A, Nakao S. Haematologica 2020
  •  Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan. Takamatsu H Int J Hematol. 111 4 519 2020
  •  Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, Yamamoto M, Takahashi T, Ichinohe T, Onizuka M, Atsuta Y, Kanda Y, Okamoto S, Sunami K, Takamatsu H. Hematol Oncol 37 5 586 2019
  •  Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12). Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K. Int J Clin Oncol. 24 8 966 2019
  •  Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.  Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A. Bone Marrow Transplant 54 10 1595 2019
  •  Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Hiroyuki Takamatsu (Corresponding author), Yoroidaka T, Fujisawa M, Kobori K, Hanawa M, Yamashita T, Murata R, Ueda M, Nakao S, Matsue K. Int J Hematol. 109 4 377 2019/04/01
  •  Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents. Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A. Bone Marrow Transplant. 2019/02/19
  •  Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society. Abe Y, Sunami K, Yamashita T, Ueda M, Takamatsu H, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Matsue K. Oncotarget 10 5 595 2019/01/15
  •  Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study) Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K.  Int J Hematol. 109 4 409 2019/04/01
  •  Clinical implications of t(11;14) in patients with multiple myeloma undergoing autologous stem cell transplantation.  ⑥ Hiroyuki Takamatsu (Corresponding author), Takeshi Yamashita, Shingo Kurahashi, Takayuki Saitoh, Tadakazu Kondo, Takeshi Maeda, Hideyuki Nakazawa, Makoto Murata, Tomoko Narita, Junya Kuroda, Hisako Hashimoto, Koji Kawamura, Toshihiro Miyamoto, Sumihisa Honda, Tatsuo Ichinohe, Yoshiko Atsuta, Kazutaka Sunami.  Biol Blood Marrow Transplant 25 3 474 2019/03/01
  •  RINKETSU Dictionary: Minimal residual disease in multiple myeloma Hiroyuki Takamatsu Rinsho Ketsueki 59 8 1118 2018/08/01
  •  Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack.  Espinoza JL, Elbadry MI, Chonabayashi K, Yoshida Y, Katagiri T, Harada K, Nakagawa N, Zaimoku Y, Imi T, Takamatsu H, Ozawa T, Maruyama H, Hassanein HA, Khalifa A Noreldin A, Takenaka K, Akashi K, Hamana H, Kishi H, Akatsuka Y, Nakao S. Blood Adv. 2 4 390-400 2018/02/27
  •  A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. Takamatsu H, Wee RK, Zaimoku Y, Murata R, Zheng J, Moorhead M, Carlton VEH, Kong KA, Takezako N, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S. Br J Haematol. 183 4 664-668 2018/11/01
  •  総合内科医の臨床必須問題183問 高松 博幸 medicina 54 4 293-298 2017

Conference Presentations

  • Risk factors of SPMs after ASCT for MM before and after the introduction of PIs/IMiDs(2020/03)
  • Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) vs. Next-Generation Sequencing(conference:The 62nd ASH Annual Meeting)(2020/12/06)
  • Impact of Depth of Response on Health-related Quality of Life (HRQoL) in Non-transplant NDMM(2020/10)
  • Clinical implications of t(11;14) in patients with multiple myeloma undergoing ASCT: A Nationwide Survey in Japan by JSHCT-MM-WG.(conference:第41回日本造血細胞移植学会総会)(2019/03/07)
  • Comparison of MRD detection in autografts of patients with multiple myeloma between 8-color MFC (EuroFlow-NGF) and NGS. (conference:American Society of Hematology Annual Meeting)(2018/12/01)

show all

  • 多発性骨髄腫における微小残存病変検出の臨床的意義: 最近の話題. (conference:第43回日本骨髄腫学会学術集会、シンポジウム)(2018/05/15)
  • 多発性骨髄腫における微小残存病変検査とその臨床的意義. 第80回日本血液学会総会、教育講演。(2018/10/01)
  • Clinical implications of t(11;14) in patients with multiple myeloma who underwent autologous hematopoietic cell transplantation. The 4th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA (COMy). May 3-5, 2018, Paris, France.(2017/05/03)
  • Novel human anti-HLA-Bw4 and B61 monoclonal antibodies kill malignant B cells via CDC/ADCC while sparing normal peripheral blood cells. (American Society of Hematology Annual Meeting Abstracts #2069), Blood 2017; 130: 2069 (Atlanta, USA)(2017/12/01)
  • Comparison of MRD detection in autografts of multiple myeloma patients between EuroFlow and NGS.(2017/10/01)
  • Novel human anti-HLA-Bw4 and B61 monoclonal antibodies kill malignant B cells via CDC/ADCC while sparing normal peripheral blood cells. (American Society of Hematology Annual Meeting Abstracts #2069)(2017/12/01)
  • Implementation of MRD Testing in MM in Asia(2017/11/01)
  • Development of Novel Human Anti-HLA-Monoclonal Antibodies for Clinical Applications Using Peripheral Blood B Cells Derived from Anti-HLA Antibody-Positive Donors. (American Society of Hematology Annual Meeting Abstracts #4723), Blood 2016; 128: 4723 (San Diego, USA)(2016/12/01)
  • Development of Novel Human Anti-HLA-Monoclonal Antibodies for Clinical Applications Using Peripheral Blood B Cells Derived from Anti-HLA Antibody-Positive Donors.(conference:American Society of Hematology Annual Meeting )(2016)
  • Development of novel human anti-HLA monoclonal antibodies for clinical applications using blood derived from anti-HLA antibody positive donors(conference:The 29th Annual and International Meeting of the Japanese Association of Animal Cell Technonology)(2016/11)
  • COMPARISON BETWEEN 8-COLOR MULTIPARAMETER FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING TO DETECT MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS WHOUNDERWENT AUTO-SCT(conference:21th congress of the European Hematology Association Meeting)(2016/06)
  • Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation. (conference:American Society of Hematology Annual Meeting)(2015/12)
  • A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation(conference:American Society of Hematology Annual Meeting)(2015/12)
  • Comparison of minimal residual disease detection in multiple myeloma between multiparameter flow cytometry and deep-sequencing(conference:15th International Myeloma Workshop)(2015/09)
  • Prognostic value of minimal residual disease response assessment in multiple myeloma(2015/07)
  • Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma(conference:American Society of Hematology Annual Meeting)(2014/12)
  • A COMPARISON BETWEEN NEXT-GENERATION SEQUENCING AND ASO-QPCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA: THE CLINICAL VALUE IN ASCT SETTING(conference:19th congress of the European Hematology Association Meeting)(2014)
  • A Comparison Between Next-Generation Sequencing and ASO-qPCR For Minimal Residual Disease Detection In Multiple Myeloma(conference:American Society of Hematology Annual Meeting)(2013/12)
  • Significance of the ISS and IMWG response criteria in patients with multiple myeloma who received ASCT in the novel agent era: a retrospective analysis of 1701 Japanese patients(conference:18th congress of the European Hematology Association Meeting)(2013)
  • A comparison between next-generation sequencing and ASO-qPCR for minimal residual disease detection in multiple myeloma(conference:18th congress of the European Hematology Association Meeting)(2013)
  • A comparison between next-generation sequencing and ASO-qPCR for minimal residual disease detection in multiple myeloma(conference:American Society of Clinical Oncology Annual Meeting)(2013)
  • A comparison between next-generation sequencing and ASO-qPCR for MRD detection in multiple myeloma(conference:14th International Myeloma Workshop)(2013/04)
  • Detection of Minimal Residual Disease in Patients with Multiple Myeloma by PCR-Based IGH Gene Clonality Analysis Using DNA Extracted From Archival Bone Marrow Slides(conference:American Society of Hematology Annual Meeting)(2011/12)
  • Role of Moesin in Murine Hematopoiesis(conference:American Society of Hematology Annual Meeting)(2011/12)
  • Identification of a Novel Auto-Antibody Highly Prevalent in Patients with Hepatitis-Associated and Idiopathic Aplastic Anemia(conference:American Society of Hematology Annual Meeting)(2009/12)
  • Roles of autoantibodies in the pathophysiology of bone marrow failure syndromes(conference:The 4th Asian Hematology Seminar)(2009/02/20)
  • Specific Antibodies to Moesin, a Membrane-Cytoskeleton Linker Protein, Are Frequently Detected in Patients with Immune-Mediated Aplastic Anemia(conference:American Society of Hematology Annual Meeting)(2005/12)
  • Stimulation of TNF- Production from Monocytes by Anti-Moesin Antibodies in the Serum of Patients with Aplastic Anemia: A Novel Mechanism of Myelosuppression by Autoantibodies(conference:American Society of Hematology Annual Meeting)(2006/12)
  • Study of hybridoma cells' kinetics in high-density culture(conference:Asian-Pacific Biochemical Engineering Conference)(1992)
  • Prognostic value of sequencing-based minimal residual disease detection in multiple myeloma.(conference:The 76th Annual Meeting of the Japanese Society of Hematology)(2014/10)

Others

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○「サイトカイン産生を誘導する自己抗体を用いた骨髄不全モデルマウスの作成 」(2009-2011) 
○「自己抗体とCLIP置換型Ii鎖ライブラリーを利用した再生不良性貧血自己抗原の同定 」(2007-) 
○「自己抗体による免疫担当細胞からのサイトカイン分泌増強を介した骨髄不全病態の解析 」(2007-) 
○「再生不良性貧血における免疫抑制療法の効果予測法の確立 」(2006-) 
○「患者B細胞を用いたモノクローナル抗体作製とその臨床応用」(2018-2020) 
○「次世代シークエンサーと蛋白質アレイを用いた骨髄腫病態解析と新規治療法の開発」(2015-2017) 

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

Classes (Graduate Schools)

○The Human Body in Health and Disease Curriculum 4(2019)
○Introduction to Molecular Biology of Cancer(2019)
○Itemized Lectures on Clinical Oncology(2019)
○Overview of Cellular Transplantation Biology(2019)
○The Human Body in Health and Disease Curriculum 4(2018)
○Itemized Lectures on Clinical Oncology(2018)
○Overview of Cellular Transplantation Biology(2018)
○Introduction to Molecular Biology of Cancer(2018)
○Introduction to Molecular Biology of Cancer(2017)
○Itemized Lectures on Clinical Oncology(2017)
○Introduction to Molecular Biology of Cancer(2017)
○Itemized Lectures on Clinical Oncology(2017)
○Overview of Cellular Transplantation Biology(2017)
○Overview of Cellular Transplantation Biology(2017)
○Itemized Lectures on Clinical Oncology(2016)
○Overview of Cellular Transplantation Biology(2016)
○Itemized Lectures on Clinical Oncology(2016)
○Introduction to Molecular Biology of Cancer(2016)
○Overview of Cellular Transplantation Biology(2016)
○Introduction to Molecular Biology of Cancer(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top